Munich Biotech files for insolvency

Cancer play Munich Biotech (Neuried, Germany) said it filed for insolvency last week. The company's MBT-0206 intravenous paclitaxel is in Phase II testing to treat metastatic breast cancer and metastatic pancreatic cancer. The company's MBT-0312 intravenous camptothecin started Phase I testing to treat metastatic solid tumors last December. Both products are formulated with Munich Biotech's EndoTag tumor endothelial cell targeting technology. ...